Working… Menu

Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04138381
Recruitment Status : Recruiting
First Posted : October 24, 2019
Last Update Posted : October 23, 2020
Information provided by (Responsible Party):
Grupo Espanol de Investigacion en Sarcomas

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 16, 2022
Estimated Study Completion Date : December 1, 2022